Vivos Therapeutics Files 8-K: Agreements, Debt, and Equity Sales
Ticker: VVOS · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Vivos Therapeutics dropped an 8-K detailing new deals, debt, and stock sales. Watch this space.
AI Summary
On June 9, 2025, Vivos Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or operations, as indicated by the filing of an 8-K. The company also reported on the creation of a direct financial obligation and unregistered sales of equity securities, suggesting recent capital raising activities or debt incurrence. The filing details these events and includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions by Vivos Therapeutics, including potential new financial obligations and equity transactions, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing mentions material definitive agreements, direct financial obligations, and unregistered sales of equity, which can signal financial restructuring or dilution risks.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of Report
- June 9, 2025 (date) — Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39796 (identifier) — SEC File Number
FAQ
What type of material definitive agreement did Vivos Therapeutics enter into?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What is the nature of the direct financial obligation or off-balance sheet arrangement?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specific details are not provided in this excerpt.
When were the unregistered sales of equity securities made?
The filing mentions unregistered sales of equity securities as an event, but the specific date of these sales is not detailed in the provided text.
What are the key financial statements and exhibits included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these documents is not detailed in the provided text.
What was Vivos Therapeutics' former company name?
Vivos Therapeutics, Inc.'s former company name was Vivos BioTechnologies, Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Vivos Therapeutics, Inc. (VVOS).